Drugs / Carcinoembryonic Antigen-Expressing Measles Virus
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00390299 | Oct 2006 → Nov 2018 | anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, mixed glioma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00408590 | Apr 2004 → Aug 2012 | ovarian carcinoma, peritoneal carcinoma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carcinoembryonic Antigen-Expressing Measles Virus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00390299 ↗ |
| Known as | MV-CEA | “Determine the safety and toxicity of recombinant carcinoembryonic antigen (CEA)-expressing measles virus (MV-CEA) and oncolytic measles virus encoding thyroidal sodium iodide...” NCT00408590 ↗ |
| Route | Other | “Given via injection into resection cavity or around tumor bed and/or IT” NCT00390299 ↗ |